Finding proteins that hit the mark


Martin LeBlanc

President and CEO, Caprion Biosciences Inc.
Chairman, Personalized Medicine Partnership for Cancer

A co-founder of Caprion, Martin has led the development of Caprion's proprietary proteomics and immune monitoring technologies and of its profitable and rapidly growing service business in the field of drug discovery and personalized medicine. Under his leadership as CEO since 2007, Caprion has more than tripled the number of employees and dramatically increased the revenues and operating profits by building successful customer relationships and strategic alliances with over 50 major pharmaceutical and biotechnology companies as well as with leading government agencies and academic institutions. He also concluded two successful acquisitions as well as the sale of Caprion to Chicago Growth Partners, a leading healthcare private equity firm.

Prior to Caprion, Martin began his professional career as a management consultant with McKinsey & Company. He then initiated his career as a biotech entrepreneur at Advanced Bioconcept, initially as Vice-President of Sales & Marketing and then as General Manager following the company's acquisition by NEN Life Sciences (now part of Perkin-Elmer).

Martin is currently a member of the Board of Directors of Caprion, Cytovance Biologics, Softbox Systems, Mispro Biotech Services, Montreal InVivo, the Atlantic Cancer Research Institute, the Personalized Medicine Partnership for Cancer (as chairman) and the Quebec Personalized Healthcare Network. He is also a member of the Governing Council of the Canadian Institutes of Health Research (CIHR), and of the Investment Committee of Amorchem.

Martin earned his bachelor's degree in Economics from the University of Moncton prior to completing an M.A. in Economics and Politics at Oxford University as a Rhodes Scholar.


Daniel Chelsky, Ph.D.

Chief Scientific Officer

Dan brings to Caprion Proteomics deep industrial experience in applying the ProteoCarta™ (formerly CellCarta®) proteomics platform to drug target and biomarker discovery.

Prior to joining the Company, Dan was President and General Manager of BioSignal Packard Inc. (a division of Perkin Elmer), where he oversaw the development of novel technologies and reagents for drug discovery and genomics research, including the AlphaScreen™ and BRET2™ technologies and product lines. Dan also spent five years at Pharmacopeia where, as Senior Director of Biology, his team identified many lead compounds from Pharmacopeia’s million member combinatorial chemistry libraries that resulted in multiple compounds in the clinic. His previous experience also includes positions at Onyx Pharmaceuticals and the DuPont Merck Pharmaceutical Company in cancer research.

Dan received his B.Sc. from the University of California at Santa Barbara and his Ph.D. in Chemistry from the University of Oregon Institute of Molecular Biology and was an American Cancer Society fellow at the University of California at Berkeley.


Normand Rivard, M.Sc.

Senior Vice-President and Chief Financial Officer

Normand joined Caprion in July 2014. He has global responsibility for leading finance functions for the company, with particular focus on supporting strategic growth initiatives by representing the company with potential investors and business partners. Normand brings a solid financial background, impressive executive leadership skills and a vast array of connections in the life sciences industry and investment community. Prior to Caprion, Normand held the position of President & CEO at Victhom Human Bionics, a publically-traded medical device company and previously was the Vice President Finance of MOXXI Medical, CFO of NSI Global Inc. and Speedware Corporation Ltd and as a Director of High Tech Financing at BNP Paribas.

Normand received his Masters of Science Degree in International Finance from HEC Montreal and Bachelor of Business Administration in Finance from UQAM Montreal.


Carol Berry, MBA

Senior Vice-President and Chief Business Officer

Carol has over 25 years of executive management experience in the diagnostic, medical device, and biotechnology industry. Carol joined Caprion in January 2014 as the Chief Business Officer and Sr. Vice President responsible for the commercial strategy and activities related to business development, marketing, product development, and customer service.

Prior to joining Caprion, Ms. Berry served as the Senior Vice President and General Manager for Asuragen's Genomic Services and CLIA Laboratory Division. From 2002 to 2007 Carol was a member of the senior management team at Ciphergen Biosystems Inc., a proteomic equipment and pharmacoproteomic research company. At Ciphergen she was responsible for diagnostic business development, sales and marketing, and assessing new potential diagnostic discoveries viable for commercialization. Ms. Berry served as the Vice President of Sales/Marketing for Dynacare Laboratories for three years where she was instrumental in expanding Dynacare's market share to a national ranking through acquisitions, strategic partnerships with hospitals, and organic sales growth nationwide. Ms. Berry started her diagnostic career at Roche Biomedical Laboratories where she was one of the top fifty General Managers from 1986 to 1996.

Carol received her Bachelor of Science Degree from Texas A&M University where she was a four year Letterman on the Women's Golf Team. She received her MBA-Information Technology Degree from University of Dallas in 2004.


Patrick Tremblay, Ph.D.

Senior Vice-President, Corporate Development and Diagnostics

Patrick joined the Caprion team in 2011. He is a biopharmaceutical and investment executive with broad expertise in R&D and business development. He is leading the corporate strategies and the development of innovative diagnostics based on proteomic discoveries made at Caprion for indications such as cancer, as well as metabolic and infectious diseases.

Prior to joining Caprion, Patrick has worked with Pappas Ventures, a US-based venture capital firm that guided the development of more than 50 life science companies in therapeutics, diagnostics, medical devices and personalized medicine. He held positions as Vice-President of R&D at BioAxone and as Director of Pharmacology at Neurochem where he developed neuroprotective and neuroregenerative drugs for Alzheimer’s disease and spinal cord injury. He was also Assistant Professor in Neurology at the University of California in San Francisco where he worked on neurodegenerative diseases induced by prions and was part of the Nobel Laureate Team of Stanley Prusiner, Medicine and Physiology (1997).

Patrick has been involved in many innovative life science initiatives. He is one of the co-founders of the Personalized Medicine Partnership for Cancer and was intimately involved in the creation and financing of the new Neomed Institute. In recent years, he has held numerous advisory positions with diverse organizations such as the Campus des Technologies de la Santé, Quebec Consortium for Drug Discovery, Centre of Excellence for Commercialization and Research of the Montreal Neurological Institute and at Pharmacology Institute of Sherbrooke University. He is presently a member of the Board of Directors of Univalor.

Patrick holds a B.Sc. degree in Microbiology and Immunology from McGill University and a Ph.D. in Molecular Biology from the University of Montreal. He has also completed post-doctoral studies at the Max Planck Institute for Biophysical Chemistry in Germany.


Lorella Di Donato, Ph.D.

Senior Vice-President, Scientific Operations

Lorella is responsible for scientific operations of Caprion’s proteomics site in Montreal, Québec. She oversees scientific and technical sample preparation/processing, mass spectrometry and bioinformatics and leads a team that provides complete offering from discovery through validation. She is also responsible for the Quality Management System (GLP) within the operation to support drug development programs (pre-clinical and clinical) for quantitative assessment of protein biomarker(s), biologics and biosimilars (PK assays). Validation of these types of assays as well as analysis of study samples are performed in accordance with FDA and EMA bioanalytical methods validation guidelines.

Before joining Caprion, Lorella was Vice-President of the Analytical Operations at Cirion BioPharma Research and was responsible for technology transfer, method development and validation of biomarker, PK and immunogenicity assays to support the development of biologic and biosimilar drug products at the pre-clinical and clinical stages. Lorella received her Ph.D. in biochemistry from the University of Montréal and has over 15 years’ experience in the CRO bioanalytical area for both small and large molecules. She has extensive knowledge of regulatory requirements for more than 500 validated methods.


Laura McIntosh, Ph.D.

Vice President, Translational Research

Laura is responsible for the scientific management of client programs at Caprion. She brings significant industrial experience in drug and device development, including the design, management and regulatory aspects of preclinical and clinical studies.

Before joining Caprion, Laura was President and General Manager of Osprey Pharmaceuticals, where she oversaw the development of a platform of therapeutic proteins for the modulation of inflammation. Her previous experience also includes positions at ART Advanced Research Technologies, where she developed a novel optical molecular imaging device, and Argose Inc, where she was involved in the development of a non-invasive glucose monitoring technology.

Laura earned a Ph.D. in Cell Biology from the University of Manitoba, followed by a post-doctoral fellowship at the National Research Council of Canada.


Eustache Paramithiotis, Ph.D.

Vice President, Biomarker Discovery and Diagnostics

Eustache is responsible for the advancement of Caprion’s diagnostics development pipeline and is involved in the development of privately and publically funded biomarker discovery programs.

He has led the development of new biology applications for the ProteoCarta™ platform in diverse disease areas such as oncology, inflammation, and metabolic disease, and has broad experience in target protein and biomarker discovery. He was the Principal Investigator of Caprion’s NIH/NIAID and CQDM funded programs in infectious disease and diabetes. Prior to the development of the ProteoCarta™ platform Eustache led Caprion’s mad cow disease diagnostic development program, resulting in the development of conformation-specific antibodies against aberrantly folded prion protein.

Eustache holds a B.Sc. in Biology from Concordia University and a Ph.D. in Immunology from McGill University. He did post-doctoral research in immune system development and memory at the Howard Hughes Medical Institute at the University of Alabama at Birmingham with an award from the prestigious Irvington Institute for Immunological Research.


Benoit Houle, Ph.D.

Vice-President, Business Development

Benoit joined Caprion in 2009 with a strong, multidisciplinary background covering pharmacology, proteomics, genomics and business development. As Vice-President, Business Development, Benoit works closely with the business and science teams, both internally and with Caprion’s and ImmuneCarta’s partners, to provide support for all contractual aspects and to allow Caprion to radiate globally as the leader in proteomic and immune monitoring services.

Benoit received his Ph.D. in molecular biology, studying molecular mechanisms of cancer, work that he pursued as a post-doctoral fellow at M.I.T. and the Fred Hutchinson Cancer Research Center. Benoit acquired extensive experience in the private biotech industry, successively occupying positions of Associate Director of Custom Services at BioSignal PerkinElmer, Director of Operations in charge of the Genome Quebec proteomics platform and Senior Director, Technology Development at Genizon.





© 2017 Caprion